Nutra Pharma Corp (NPHC) stock
Close on Oct 19, 2026Market cap $806.69KP/E –Yield –
Nutra Pharma Corp saw revenue fall 49.0% to $160.82K over the twelve months to Jun 30, 2026. Free cash flow was -$1.19M. At the latest close the market valued the company at $806.69K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $806.69K
- P/E ratio
- –
- Price to sales
- 5.02
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -147.52%
Fundamentals
- Revenue
- $160.82K
- Net income
- -$5.42M
- EPS, diluted
- $0.00
- Free cash flow
- -$1.19M
- Book value per share
- -$0.00
- Diluted shares
- 8.07B
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 928,010
- Average volume (20 days)
- 319,392
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | NPHC | S&P 500 | Difference | NPHC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | -66.7% | +3.4% | −70.0 pts | ||
| Year to date | 0.0% | +13.3% | −13.3 pts | ||
| 1 year | 0.0% | +16.6% | −16.6 pts | ||
| 3 years | 0.0% | +86.4% | −86.4 pts | 0.0% | +23.1% |
| 5 years | -96.4% | +81.9% | −178.3 pts | -48.6% | +12.7% |
| 10 years | -99.2% | +318.9% | −418.0 pts | -38.0% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nutra Pharma filed with the SEC as exhibits to Form 8-K or 6-K
About Nutra Pharma
Medicinal Chemicals & Botanical Products
Nutra Pharma Corp. is a biopharmaceutical company focused on the acquisition, licensing, and commercialization of pharmaceutical technologies, homeopathic treatments, and ethical drugs. Its research and development efforts target products for autoimmune conditions, neurological disorders, viral infections, and chronic pain management. The company's consumer offering includes over-the-counter pain relief remedies such as Nyloxin, Pet Pain-Away for cats and dogs, Equine Pain-Away for horses, and Luxury Feet for footwear-related discomfort. In addition to its consumer formulations, the company serves third-party distributors and partners, such as Avini Health, by providing formulation and contract manufacturing services for private-label goods and dietary supplements.
Company profile, executives and historyNutra Pharma stock: common questions
What is Nutra Pharma's stock price?
NPHC closed at $0.00 on Oct 19, 2026, up 0.00% on the day.
What is Nutra Pharma's market cap?
Nutra Pharma was worth $806.69K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is NPHC's P/E ratio?
Nutra Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Nutra Pharma make?
Nutra Pharma reported revenue of $160.82K for the twelve months to Jun 30, 2026, down 49.0% from a year earlier.
Does Nutra Pharma pay a dividend?
No. Nutra Pharma has not paid a cash dividend over the last twelve months.
How has NPHC stock performed over the past year?
Including dividends, NPHC returned 0.0% over the past year, against +16.6% for the S&P 500.
Who are Nutra Pharma's competitors?
Companies most similar to Nutra Pharma by business, industry and size include LEXX, ASBP, ZIVO, CFOO, ABVC.
See a number that looks wrong?